FORUM PHARMACEUTICALS INC.
Patent Owner
Stats
- 16 US PATENTS IN FORCE
- 2 US APPLICATIONS PENDING
- Aug 31, 2017 most recent publication
Details
- 16 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 162 Total Citation Count
- Oct 26, 2007 Earliest Filing
- 17 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2017/0247,393 Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine ReceptorsOct 12, 16Aug 31, 17[C07D]
2017/0044,155 Geminal Substituted Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine ReceptorsAug 10, 16Feb 16, 17[C07D]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9550767 Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrateJan 20, 16Jan 24, 17[A61K, C07D, C30B]
9273044 Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrateJul 09, 15Mar 01, 16[A61K, C07D]
9193749 Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitorsFeb 14, 13Nov 24, 15[C07H, C07D]
9108961 Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochlorideFeb 19, 14Aug 18, 15[A61K, C07D]
8815933 Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereofFeb 07, 14Aug 26, 14[A61K, C07D]
8710227 Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrateMay 17, 11Apr 29, 14[A61K, C07D]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2017/0000,749 Methods for Treating Cognitive Disorders Using Inhibitors of Histone DeacetylaseAbandonedFeb 04, 16Jan 05, 17[A61K]
2016/0222,026 Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC InhibitorsAbandonedSep 14, 15Aug 04, 16[C07D, C07C]
2015/0265,583 Treatment of Cognitive Disorders with (R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-Carboxamide and Pharmaceutically Acceptable Salts ThereofAbandonedOct 08, 14Sep 24, 15[A61K]
2015/0126,546 Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptors in Combination with Acetylcholinesterase InhibitorsAbandonedJun 17, 14May 07, 15[A61K]
2015/0080,325 METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASEAbandonedApr 01, 14Mar 19, 15[C07H, C07D, C07C]
2014/0179,678 METHODS OF TARGETED TREATMENT OF FRONTOTEMPORAL LOBAR DEGENERATIONAbandonedMar 26, 12Jun 26, 14[C07D]
2014/0163,067 Methods of Treatment of Limited Cognitive ImpairmentAbandonedJun 28, 12Jun 12, 14[C07D]
2014/0155,429 Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with NicotineAbandonedMay 08, 12Jun 05, 14[A61K, C07D]
2014/0148,479 Treatment of Cognitive Disorders with (R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-Carboxamide and Pharmaceutically Acceptable Salts ThereofAbandonedDec 23, 13May 29, 14[A61K]
2013/0231,365 Treatment of Inflammation with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase InhibitorsAbandonedNov 18, 11Sep 05, 13[A61K]
2013/0225,560 Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase InhibitorsAbandonedJul 25, 11Aug 29, 13[A61K]
2011/0288,070 METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASEAbandonedMay 05, 09Nov 24, 11[A61K, A61P]
2011/0124,631 TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTORS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORSAbandonedDec 27, 10May 26, 11[A61K, A61P]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.